Plain-English translation of NCT06431919 on ClinicalTrials.gov ↗ ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Cirrhosis can weaken the heart over time, even when the heart looks normal on the surface. This trial is testing whether adding simvastatin, a cholesterol medication, to carvedilol (a heart medication already known to help) might provide extra protection. Researchers want to see if this combination helps prevent serious complications and improve survival in people with cirrhosis and heart dysfunction.
Current treatments slow down heart rate to reduce stress on the heart, but many patients with cirrhosis struggle to tolerate the high doses needed. This medication combination might offer additional heart protection through a different mechanism, potentially helping more patients avoid life-threatening complications like kidney failure or heart failure.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the heart medication alone or the heart medication plus the cholesterol medication. The heart medication starts at a low dose and is gradually increased every week to reach a target heart rate, while the cholesterol medication stays at a fixed dose. You'll take these medications daily while receiving standard medical care, and the study team will monitor your heart function and liver health over time through clinic visits and testing.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
India